BioHarvest Sciences (BHST) Expected to Announce Earnings on Thursday

Key Points

• BioHarvest is expected to report Q4 2025 results before market open on Thursday, April 23, with analysts forecasting EPS of ($0.11) and revenue of about $9.24 million (company call details list a March 31, 2026 call).
• Shares opened at $4.30 with a market cap of $84.35 million, a 1‑year range of $4.10–$12.80, 50‑/200‑day moving averages of $4.44/$6.24, and a negative P/E of -7.05.
• Institutional buying has increased (notably Alyeska’s new ~$3.93M stake), while analyst views are mixed—Roth MKM initiated a Buy at $10, Weiss Ratings reaffirmed a Sell (d-), and the consensus is Hold with a $12.50 target.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Thursday, April 23rd. Analysts expect BioHarvest Sciences to post earnings of ($0.11) per share and revenue of $9.2390 million for the quarter. Interested persons may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:30 PM ET.

BioHarvest Sciences Price Performance

Shares of BioHarvest Sciences stock opened at $4.30 on Thursday. The company has a current ratio of 3.97, a quick ratio of 3.38 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $84.35 million, a price-to-earnings ratio of -7.05 and a beta of 1.16. BioHarvest Sciences has a 1-year low of $4.10 and a 1-year high of $12.80. The firm's 50-day moving average price is $4.44 and its two-hundred day moving average price is $6.24.

Institutional Trading of BioHarvest Sciences

Several hedge funds have recently modified their holdings of the stock. Alyeska Investment Group L.P. bought a new stake in shares of BioHarvest Sciences during the fourth quarter valued at approximately $3,929,000. Evercore Wealth Management LLC bought a new stake in shares of BioHarvest Sciences during the fourth quarter valued at approximately $724,000. Osaic Holdings Inc. grew its stake in shares of BioHarvest Sciences by 5,510.4% during the fourth quarter. Osaic Holdings Inc. now owns 35,233 shares of the company's stock valued at $183,000 after purchasing an additional 34,605 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of BioHarvest Sciences during the fourth quarter valued at approximately $173,000. Finally, Jane Street Group LLC bought a new stake in shares of BioHarvest Sciences during the fourth quarter valued at approximately $145,000.

Analyst Ratings Changes

Several brokerages have weighed in on BHST. Roth Mkm began coverage on shares of BioHarvest Sciences in a research note on Thursday, February 19th. They set a "buy" rating and a $10.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioHarvest Sciences in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $12.50.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.